Navigation Links
AutoImmune Inc. Reports 2009 First Quarter Financial Results
Date:5/7/2009

PASADENA, Calif., May 7 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net loss of $170,000, or $0.01 per share basic and diluted, for the three months ended March 31, 2009, compared with a net loss of $107,000, or $0.01 per share basic and diluted, for the three months ended March 31, 2008. As of March 31, 2009, the Company reported $8.5 million in cash and marketable securities, the same amount reported as of December 31, 2008.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "Product sales in the first quarter of 2009 at Colloral LLC, our joint venture with Deseret Laboratories, Inc., were up from the fourth quarter of 2008 and from the first quarter of 2008. The response to marketing through our licensee, Bronson Laboratories, LLC remains encouraging." AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46R "Consolidation of Variable Interest Entities."

AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS Medical Corp., a Canadian company. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug, dirucotide (formerly referred to as MBP8298), if it reaches the market. In December 2007, BioMS sublicensed its rights in this product to Eli Lilly and Company. The FDA has granted the product fast track designation. We expect final trial data will be available during the second half of 2009 from the first of two ongoing Phase III trials of dirucotide for the treatment of secondary progressive multiple sclerosis. We expect results from the second Phase III trial should be available during the last half of 2010.

AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

Statements in this release that are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. Statements in this release that are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to the uncertainties of clinical trial results, AutoImmune's dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed, as are other factors, in AutoImmune's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission in the section entitled "Risk Factors."

                            - Financial Chart Follows -



                                  AUTOIMMUNE INC.
                              STATEMENT OF OPERATIONS
                                    (Unaudited)

                                                           Three months ended
                                                                March 31,
                                                            2008        2009
                                                            ----        ----

      Revenue                                            $67,000    $104,000
                                                         -------    --------


      Costs and expenses:
        Cost of goods sold                                12,000      20,000
        Research and development                          42,000      71,000
        General and administrative                       205,000     188,000
                                                         -------     -------
          Total costs and expenses                       259,000     279,000
                                                         -------     -------

      Interest income                                     84,000       9,000
                                                          84,000       9,000
                                                          ------       -----

      Net loss                                          (108,000)   (166,000)
        Net income (loss) attributable to
         noncontrolling interest                           1,000      (4,000)
                                                           -----      ------

      Net loss attributable to AutoImmune Inc          ($107,000)  ($170,000)
                                                       =========   =========

      Net loss per share - basic                          ($0.01)     ($0.01)
                                                          ======      ======

      Net loss per share - diluted                        ($0.01)     ($0.01)
                                                          ======      ======

      Weighted average common shares
        outstanding - basic                           16,997,205  16,999,623
                                                      ==========  ==========

      Weighted average common shares
        outstanding - diluted                         16,997,205  16,999,623
                                                      ==========  ==========




                              CONDENSED BALANCE SHEET
                                    (Unaudited)

                                                    December 31,   March 31,
                                                        2008        2009
                                                        ----        ----


      Cash and marketable securities                  $8,475,000  $8,463,000
      Other current assets                               195,000     148,000

        Total assets                                  $8,670,000  $8,611,000
                                                      ==========  ==========

      Current liabilities                               $147,000    $228,000
      Total equity                                     8,523,000   8,383,000
                                                       ---------   ---------

      Total liabilities and equity                    $8,670,000  $8,611,000
                                                      ==========  ==========


'/>"/>
SOURCE Autoimmune Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
2. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
3. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
4. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
5. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
6. Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market
7. AutoImmune Inc. Reports 2008 Fourth Quarter and Year End Financial Results
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... American Process, Inc. ... patents, U.S. Patent Nos. 9,322,133 and 9,322,134, to API and its affiliated companies ... well as hydrophobic nanocellulose compositions. In addition to these patents and U.S. ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... further than LaJollaCooks4u, San Diego’s premiere hands-on cooking experience. Offering everything from gourmet ... mom an experience she won’t forget. , Guests that visit LaJollaCooks4u share an ...
(Date:5/4/2016)... May 4, 2016 According to ... "Metabolomics Market - Global Industry Analysis, Size, Share, Growth, ... is anticipated to expand at a CAGR of 17.1% ... by 2024. Metabolomics is the extensive study ... biofluids, tissues or organisms. Together, these small molecules and ...
(Date:5/3/2016)... ... May 03, 2016 , ... Morf Media Inc ... training platform on mobile devices, today released a new interactive Food and ... Devices. The course is essential for owners or operators of places of business ...
Breaking Biology Technology:
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/21/2016)... March 22, 2016 Unique ... passcodes for superior security   ... provider of secure digital communications services, today announced it ... and offer enterprise customers, particularly those in the Financial ... and voice authentication within a mobile app, alongside, and ...
(Date:3/14/2016)... March 14, 2016 NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ... week of March 21 st .  The commercials will air ... popular Squawk on the Street show. --> NXTD ... growing mobile commerce market, announces the airing of a new ...
Breaking Biology News(10 mins):